No profile data available.
BioAtla, Inc. (BCAB) is a healthcare company in the additional cancer treatment drugs industry, based in San Diego, United States, with about 41 full-time employees.
It reported revenue of $11.00 million for fiscal year 2024, and net income of -$69.78 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0, down 100.0% from a year before. Its market capitalization was $2.50 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
BioAtla reported $11.00 million in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$2.50 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Silexion Therapeutics Corp (SLXN), Mustang Bio, Inc. (MBIO), Kairos Pharma, Ltd. (KAPA), Genprex, Inc. (GNPX).